Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Genitourinary Cancers Symposium
Array of Treatments for Metastatic Prostate Cancer, but Can We Afford Them?
By
Phoebe Starr
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
New York, NY—Men with castration-resistant prostate cancer (CRPC) now have several different treatments that improve their survival—docetaxel (Taxo-tere), cabazitaxel (Jevanta), abiraterone (Zytiga), and sipuleucel-T (Provenge).
Read Article
Two Mechanistically Distinct Agents Lead to Impressive Survival Improvements in Advanced Prostate Cancer
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—Two treatments significantly extended survival in men with metastatic castration-resistant prostate cancer (CRPC) in separate phase 3 clinical trials reported at the 2012 Genitourinary Cancers Symposium.
Read Article
Comparative Effectiveness Analysis of 3 Radiation Therapies for Prostate Cancer
By
Wayne Kuznar
Genitourinary Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—A new, large comparative effectiveness analysis of 3 techniques for delivering radiation therapy for the treatment of localized prostate cancer supports intensity-modulated radiation therapy (IMRT) as the current standard, said Ronald Chen, MD, MPH, Assistant Professor of Radiation Oncology, University of North Carolina (UNC), Chapel Hill, and Research Fellow, Sheps Center for Health Services Research, UNC at the 2012 annual Genitourinary Cancers Symposium.
Read Article
Sorafenib Active Third-Line in Refractory GIST
By
Caroline Helwick
Genitourinary Cancers Symposium
April 2011, Vol 2, No 2
Read Article
Hypertension a Good Sign in Patients Receiving Sunitinib
Genitourinary Cancers Symposium
April 2011, Vol 2, No 2
Read Article
Future of Colorectal Cancer Therapy: Novel Targeted Pathways
By
Caroline Helwick
Colorectal Cancer
,
Genitourinary Cancers Symposium
April 2011, Vol 2, No 2
Read Article
Competing Tests for Colorectal Cancer Risk Recurrence
By
Caroline Helwick
Colorectal Cancer
,
Genitourinary Cancers Symposium
April 2011, Vol 2, No 2
Read Article
Potential New Options for Neuroendocrine Prostate Cancer
Genitourinary Cancers Symposium
,
Prostate Cancer
April 2011, Vol 2, No 2
Read Article
Large Study Rules PSA Test Unnecessary >10 Years after Radical Prostatectomy
By
Debra Wood, RN
Genitourinary Cancers Symposium
April 2011, Vol 2, No 2
Read Article
CyberKnife Cost-Effective in the Long-Term
By
Debra Wood, RN
Genitourinary Cancers Symposium
,
Prostate Cancer
April 2011, Vol 2, No 2
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma